Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Antidiabetic Carcinogenicity Data Look Clean; NDA Filing By Year-End?

This article was originally published in The Pink Sheet Daily

Executive Summary

With 80% of data reported, Bristol has "not seen anything that would concern us" about muraglitazar. NDA would be the first in the dual PPAR class after repeated development failures for similar compounds.

You may also be interested in...



AstraZeneca's Galida Filing Delayed Until 2007 Due To PPAR Safety Concerns

Long-term patient follow-up is extended to two years in light of regulatory concerns about PPAR class safety, firm tells analysts. News is setback for AstraZeneca's near-term cardiovascular pipeline and a boost for Bristol/Merck's muraglitazar.

AstraZeneca's Galida Filing Delayed Until 2007 Due To PPAR Safety Concerns

Long-term patient follow-up is extended to two years in light of regulatory concerns about PPAR class safety, firm tells analysts. News is setback for AstraZeneca's near-term cardiovascular pipeline and a boost for Bristol/Merck's muraglitazar.

Merck Gets Second Chance On Dual PPAR: Will Co-Develop Bristol's Muraglitazar

Bristol cites shift in focus to specialty care as one reason to out-license the product. Merck will pay $100 mil. upfront and $275 mil. in milestone payments for rights to the dual PPAR agonist and a back-up compound in Phase II.

Topics

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel